Skip to main content

Advertisement

SpringerLink
Log in

Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment

  • Original Paper
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

The aim of this study was to develop a reliable and valid short version of the Udvalg for Kliniske Undersogelser (UKU) to efficiently evaluate the side effects of antipsychotics in patients with schizophrenia. This multi-site study included 10 hospitals, which included 331 inpatients and outpatients diagnosed with schizophrenia. UKU, Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP) and dosage of paliperidone were collected. The predictive validity of the UKU-short version, as well as that of the CGI-S, PSP and paliperidone dosages, was analyzed using structural equation modeling (SEM), latent growth models (LGM), and confirmatory factor analysis to test its content and construct validity. The UKU-short included nine-items of sedation, reduced sleep, rigidity, tremor, akathisia, headache, reduced salivation, constipation and orthostatic dizziness, and has good construct and content validity over time. Confirmatory factor analysis showed good construct validity, with the psychic, neurological and autonomic side effect dimensions having correlations between 0.60 and 0.71. The predictive validity of the short-version UKU for psychiatric symptoms (CGI-S), quality of life (PSP) and dosage showed that the effects of drug dosage were negligible, and only neurological side effects were associated with psychiatric symptoms and quality of life. The UKU-short showed good content, construct and predictive validity. It is a more time-efficient instrument than the original UKU. This study only included patients treated with paliperidone, larger scale studies is needed to validate the UKU-short in detection of side effects in routine clinical practice to prevent non-adherence in patients with schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Donohoe G, Owens N, O'Donnell C et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry 2001;16:293-8.

    Article  CAS  PubMed  Google Scholar 

  2. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54:665-777.

    Article  PubMed  Google Scholar 

  3. Velligan DI, Weiden PJ, Sajatovic M et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009;70 Suppl 4:1-46.

    PubMed  Google Scholar 

  4. Kane JM. Dosage and route of administration of neuroleptic drugs during different phases of schizophrenia illness. In: Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer; 1994.

    Google Scholar 

  5. Lader M, Lewander T. The neuroleptic-induced deficit syndrome. Acta Psychiatr Scand. 1994;89 (Suppl 380):1-85

    Google Scholar 

  6. Day JC, Wood G, Dewy M, Bentall RP. A self-rating scale for measuring neuroleptic side effects: Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-3

    Article  CAS  PubMed  Google Scholar 

  7. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71

    Article  CAS  PubMed  Google Scholar 

  8. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 2005;20:15-27.

    Article  PubMed  Google Scholar 

  9. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 2000;148:3-15.

    Article  CAS  PubMed  Google Scholar 

  10. Piparva KG, Buch JG, Chandrani KV. Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD. Indian J Psychol Med. 2011;33:153-7.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs 2012;26:601-11.

    Article  CAS  PubMed  Google Scholar 

  12. Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012;43:906-13.

    Article  PubMed  Google Scholar 

  13. Rosen JB, Milstein MJ, Haut SR. Olanzapine-associated myoclonus. Epilepsy Res. 2012;98:247-50.

    Article  PubMed  Google Scholar 

  14. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Legen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scand. 1987;76:1-100.

    Article  Google Scholar 

  15. Lambert TJR, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol Clin Exp. 2003;18:405-11.

    Article  CAS  Google Scholar 

  16. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine with coadministered with haloperidol, risperidone, or thioridazine. J Psychopharmacol. 2002;22:121-30.

    Article  CAS  Google Scholar 

  17. Chen YL, Cheng TS, Lung FW. Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry 2009;11:16-20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand. 1994;89:11-5.

    Google Scholar 

  19. Wang CS, Kao WT, Chen CD, Tung YP, Lung FW. Priapism associated with typical and atypical antipsychotic medications. Int Clin Psychopharmacol. 2006;21:245-8.

    Article  PubMed  Google Scholar 

  20. Lee HH, Chu YH, Ruan FF, Tzeng DS, Lung FW. Confirmatory factor analysis of the Sexual Desire Inventory for schizophrenia patients. Taiwanese Journal of Psychiatry 2007;21:176-83.

    Google Scholar 

  21. Lee HH, Lung FW, Lee PR, Kao WT, Lee YL. The relationship between sex life satisfaction and job stress of married nurses. BMC Res Notes 2012;5:445.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Seeman MV. Loss of Libido in a Woman With Schizophrenia. Am J Psychiatry 2013;170:471-5.

    Article  PubMed  Google Scholar 

  23. Ong J, Wong W, Lee A, Holroyd E, Huang SY. Sexual activity and adolescent health risk behaviours amongst high school students in three ethnic Chinese urban populations. J Clin Nurs. 2013;22:3270-9.

    Article  PubMed  Google Scholar 

  24. Tsai JK, Lin WK, Lung FW. Social interaction and drug attitude effectiveness in patients with schizophrenia. Psychiatr Q. 2011;82:343-51.

    Article  PubMed  Google Scholar 

  25. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm). Bethesda MD: National Institute of Mental Health; 1976.

    Google Scholar 

  26. Brissos S, Molodynski A, Dias VV, Figueira ML. The importance of measuring psychosocial functioning in schizophrenia. Ann Gen Psychiatry 2011;10:18.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Anastasi A, Urbina S. Psychological testing, 7th ed. New York: Prentice Hall; 1997.

    Google Scholar 

  28. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6:21-6.

    Article  CAS  PubMed  Google Scholar 

  29. Fujimaki K, Takahashi T, Morinobu S. Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS ONE 2012;7:e37087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ghisletta P, Lindenberger U. Static and dynamic longitudinal structural analyses of cognitive changes in old age. Gerontology 2004;50:12-6.

    Article  PubMed  Google Scholar 

  31. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:1225-37.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Chugh PK, Rehan HS, Unni KES, Sah RK. Predictive value of symptoms for quality of life in first-episode schizophrenia. Nord J Psychiatry 2013;67:153-8.

    Article  PubMed  Google Scholar 

  33. Yang MC, Lung FW. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide25-35, N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology 2011;217:397–410.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taipei City Hospital, Songde Branch, Taipei, Taiwan

    Kun-Po Chen

  2. Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan

    Kun-Po Chen

  3. Calo Psychiatric Center, No.12-200, Jinhua Rd., Xinpi Township, Pingtung County, 925, Taiwan

    For-Wey Lung

  4. Department of Psychiatry, National Defense Medical Center, Taipei, Taiwan

    For-Wey Lung

  5. Department of Neurology, Kaohsiung Medical University, Kaohsiung, Taiwan

    For-Wey Lung

Authors
  1. Kun-Po Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. For-Wey Lung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to For-Wey Lung.

Ethics declarations

Disclosure of Potential Conflicts of Interest

All authors have no conflict of interest to declare.

Research involving Human Participants and/or Animals

The study was approved by the institutional review board of a teaching hospital in Taiwan, and is in accordance in accordance with the ethical standards in the 1964 Declaration of Helsinki and its later amendments.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, KP., Lung, FW. Reliability and Validity of the Short Version of Udvalg for Kliniske Undersogelser in Antipsychotic Treatment. Psychiatr Q 88, 787–796 (2017). https://doi.org/10.1007/s11126-017-9494-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-017-9494-y

Keywords

Search

Navigation